| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Dimetridazole targets anaerobic bacteria and protozoa by disrupting their DNA synthesis. The nitro group of the compound is reduced by microbial enzymes, generating reactive intermediates that cause DNA damage and strand breakage. This leads to cell death in susceptible organisms. The compound is effective against Trichomonas and Histomonas species.
|
|---|---|
| ln Vitro |
In vitro, dimetridazole exhibits antiprotozoal and antibacterial activity against anaerobic organisms. Its activity is assessed by determining minimum inhibitory concentrations (MIC) against susceptible protozoa and bacteria. The compound's mechanism involves DNA damage through reductive activation of the nitro group.
|
| ln Vivo |
In vivo, dimetridazole is used in veterinary medicine for the treatment of protozoal infections, including histomoniasis (blackhead) in turkeys and trichomoniasis in cattle. It is administered orally via feed or water. The compound is effective against anaerobic bacterial infections in poultry and swine.
|
| Enzyme Assay |
In vitro enzyme assays for dimetridazole measure its effects on DNA synthesis and integrity in target organisms. The compound's reductive activation is assessed by measuring nitroreductase activity. DNA damage is evaluated using comet assays or by measuring DNA fragmentation in treated cells.
|
| Cell Assay |
In vitro cell-based assays for dimetridazole use cultures of susceptible protozoa or anaerobic bacteria. Cells are treated with serial dilutions of the compound, and growth inhibition is measured. Minimum inhibitory concentrations (MIC) are determined using broth microdilution methods.
|
| Animal Protocol |
In vivo animal models for dimetridazole include poultry and swine models of protozoal infection. The compound is administered orally, and its effects on infection clearance and clinical signs are evaluated. Pharmacokinetic studies measure drug absorption, distribution, and elimination in target species.
|
| ADME/Pharmacokinetics |
Dimetridazole has a molecular formula of C₅H₇N₃O₂ and a molecular weight of 141.13 g/mol. It is a white to off-white crystalline powder, soluble in organic solvents, and sparingly soluble in water. The compound is stored at room temperature, protected from light. It is used primarily in veterinary medicine.
|
| Toxicity/Toxicokinetics |
Dimetridazole has a well-characterized safety profile for veterinary use. Common adverse effects may include gastrointestinal disturbances. The compound is contraindicated in animals with known hypersensitivity to nitroimidazoles. It is for veterinary use only and is not approved for human use.
|
| Additional Infomation |
Metronidazole is a C-nitro compound, a 5-nitroimidazole derivative in which the hydrogen atoms at positions 1 and 2 are replaced by methyl groups. It is an antimicrobial drug and has been banned as a livestock feed additive by the Canadian government and the European Union due to suspected carcinogenicity. It can be used both as an antimicrobial drug and an antiparasitic drug. It is a C-nitro compound belonging to the imidazole class of compounds.
Dimetridazole free base is a nitroimidazole antiprotozoal and antibacterial agent used primarily in veterinary medicine. It is effective against anaerobic bacteria and protozoa, including Trichomonas and Histomonas species. The compound's mechanism involves reductive activation of the nitro group, leading to DNA damage. Dimetridazole is used for research and veterinary purposes. |
| Molecular Formula |
C5H7N3O2
|
|---|---|
| Molecular Weight |
141.1280
|
| Exact Mass |
141.053
|
| CAS # |
551-92-8
|
| Related CAS # |
Dimetridazole-d3;64678-69-9
|
| PubChem CID |
3090
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
313.7±15.0 °C at 760 mmHg
|
| Melting Point |
177-182°C
|
| Flash Point |
143.5±20.4 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.599
|
| LogP |
0.31
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
144
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[O-][N+](C1=C([H])N=C(C([H])([H])[H])N1C([H])([H])[H])=O
|
| InChi Key |
IBXPYPUJPLLOIN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H7N3O2/c1-4-6-3-5(7(4)2)8(9)10/h3H,1-2H3
|
| Chemical Name |
1,2-dimethyl-5-nitroimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~354.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.0857 mL | 35.4283 mL | 70.8567 mL | |
| 5 mM | 1.4171 mL | 7.0857 mL | 14.1713 mL | |
| 10 mM | 0.7086 mL | 3.5428 mL | 7.0857 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
